Yahoo Finance25d
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company ... the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”) granted ...
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in ...
Business Insider24d
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
The Panel’s determination follows a hearing on ... for oncology and other senescent-cell-associated diseases.” About HCW Biologics: HCW Biologics Inc. (Nasdaq: HCWB) is a clinical-stage ...
Finanznachrichten24d
HCW Biologics, Inc: HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
The Panel's determination follows a hearing on February ... for oncology and other senescent-cell-associated diseases." About HCW Biologics: HCW Biologics Inc. (Nasdaq: HCWB) is a clinical-stage ...
Yahoo Finance24d
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics ... 2025, the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”) ...